Regulatory Approvals

FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor

By

Regulatory Approvals — FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor  European Pharmaceutical Review

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. July 21, 2026.

By

Related Post

Regulatory Approvals

FDA clears combined patient warming, securement device for robotic surgery

Regulatory Approvals

FDA clears Taylor Farms as cyclospora source; Louisiana case count reaches 55

Regulatory Approvals

How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD

Financial News For All

Labor

ESPN starts layoffs tied to NFL Network acquisition, memo says

Labor

ESPN Layoffs Mostly Tied to NFL Network Acquisition: Full List

Labor

Karl Ravech, Tom Pelissero among ESPN layoffs in latest round of cuts: Sources – The Athletic

Regulatory Approvals

FDA clears combined patient warming, securement device for robotic surgery